Go Pro
NASDAQ:STEX

Biosig Technologies Q4 2025 Earnings Report

Biosig Technologies logo
$0.68 -0.03 (-4.14%)
Closing price 09/29/2026 04:00 PM Eastern
Extended Trading
$0.68 0.00 (-0.09%)
As of 09/29/2026 07:53 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Biosig Technologies EPS Results

Actual EPS
-$8.23
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Biosig Technologies Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Biosig Technologies Announcement Details

Quarter
Q4 2025
Time
After Market Closes
Conference Call Date
N/A
Conference Call Time
N/A

Earnings Documents

Biosig Technologies Earnings Headlines

Here’s the stock symbol I’ve promised
Whitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - but now he believes he's found something better. This under-the-radar company sits at the intersection of America's two most important industries, including AI, pays massive dividends, and attracted a famous money manager who put 60% of his multi-billion-dollar fund into it. Tilson is revealing the name and ticker symbol completely free - no credit card or email required.tc pixel
Streamex Corp.(NasdaqCM:STEX) dropped from S&P Global BMI Index
See More Biosig Technologies Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Biosig Technologies? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Biosig Technologies and other key companies, straight to your email.

About Biosig Technologies

Biosig Technologies (NASDAQ:STEX) is a medical technology company focused on improving the diagnosis and treatment of cardiac arrhythmias. Its primary product is the PURE EP™ Platform, an electrophysiology system designed to acquire, process, and display intracardiac and surface cardiac signals during procedures.

The PURE EP Platform is intended for use by electrophysiologists in hospitals and other clinical settings, where it can support the evaluation of abnormal heart rhythms and help guide catheter-based ablation procedures. The system is designed to provide high-fidelity signal visualization and noise reduction compared with conventional electrophysiology recording workflows.

BioSig has historically focused its commercialization efforts on the United States and has worked with hospitals, physicians, and cardiac electrophysiology specialists. The company was previously publicly traded under the symbol BSGM. Information connecting BioSig Technologies with the symbol STEX, as provided, could not be independently verified.

View Biosig Technologies Profile